Robert Lande, longtime President of Retail FX broker FXCM Group, has joined the board of directors of Uruguay based company GBT Grupo Biotoscana.

GBT is a Latin American biopharmaceutical company based on innovation. The company develops, manufactures and commercializes advanced medicines, aimed at treating unmet medical needs. Headquartered in Montevideo, Uruguay and with presence in 10 countries throughout the region, GBT includes a team of more than 600 scientists, doctors, pharmacists, regulatory professionals, sales and marketing experts, access specialists and dedicated support people spread throughout the region.

GBT’s main areas of operations are oncology, onco-hematology, severe infectious diseases, specialty treatments, immunology, inflammation, as well as certain rare diseases.

Based in New York, Robert Lande joined FXCM in 2010 as the company’s CFO, and was named President in January 2018. He does have other experience in the pharma sector, serving as a director of Canadian pharmaceutical company Knight Therapeutics since 2014.